Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitors is a research paper published in F1000Research (2023). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Grant: 1U01CA180964
National Institutes of Health
Grant: R01CA242845
Cancer Prevention and Research Institute of Texas
Grant: RP1100584
Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
Grant: UL1TR000371
MD Anderson Cancer Center Support Grant
Grant: P30 CA016672
National Institutes of Health
Grant: 5R01CA242845-04
Blocking tumor progression in therapy-responsive RET aberration-associated cancer
National Institutes of Health
Grant: 5U01CA180964-02
Informatics to enable routine personalized cancer therapy
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 4UL1TR000371-10
Center for Clinical and Translational Sciences (CCTS)
Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center
Jacquelyn A. Brady Fund
FWCI
0.00
Citation Percentile
0.3%
Fields of Study
Keywords
Sustainable Development Goals